Immatics (NASDAQ:IMTX) Short Interest Update

Immatics (NASDAQ:IMTX - Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 8,820,000 shares, a drop of 11.9% from the January 31st total of 10,010,000 shares. Based on an average daily trading volume, of 950,000 shares, the short-interest ratio is presently 9.3 days.

Immatics Trading Down 3.4 %

Immatics stock traded down $0.16 during mid-day trading on Monday, hitting $4.50. The company had a trading volume of 134,657 shares, compared to its average volume of 588,269. Immatics has a 12 month low of $4.06 and a 12 month high of $13.77. The stock's 50 day moving average price is $5.50 and its two-hundred day moving average price is $8.12. The company has a market capitalization of $537.10 million, a PE ratio of -6.74 and a beta of 0.83.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. The Goldman Sachs Group raised Immatics to a "strong-buy" rating in a research report on Monday, November 25th. Bank of America decreased their price objective on Immatics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, November 19th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $16.67.

Remove Ads

Institutional Trading of Immatics

Institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its holdings in shares of Immatics by 9.3% during the third quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company's stock valued at $1,880,000 after buying an additional 13,997 shares during the last quarter. Vestal Point Capital LP boosted its stake in Immatics by 36.4% during the 3rd quarter. Vestal Point Capital LP now owns 3,750,000 shares of the company's stock valued at $42,788,000 after purchasing an additional 1,000,000 shares during the last quarter. Braidwell LP bought a new stake in shares of Immatics in the 3rd quarter worth $18,799,000. Wasatch Advisors LP increased its holdings in shares of Immatics by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 872,511 shares of the company's stock worth $9,955,000 after purchasing an additional 29,239 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Immatics in the third quarter worth $298,000. 64.41% of the stock is currently owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.